公开(公告)号：US09920123B2

公开(公告)日：2018-03-20

申请号：US15335278

申请日：2016-10-26

Applicant: Genentech, Inc.

Inventor： Bryan Irving ,  Henry Chiu ,  Heather Maecker ,  Sanjeev Mariathasan ,  Sophie M. Lehar ,  Yan Wu ,  Jeanne Cheung

IPC: A61K39/00 ,  C07K16/28 ,  C07K16/30 ,  A61K31/7068 ,  A61K39/395 ,  A61K45/06 ,  C07K16/10 ,  C07K16/22

CPC classification number: C07K16/2827 ,  A61K31/7068 ,  A61K39/00 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/1063 ,  C07K16/22 ,  C07K16/28 ,  C07K16/30 ,  C07K16/3046 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/71 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/423 ,  Y02A50/492 ,  A61K2300/00

Abstract: The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.

公开(公告)号：US20240166741A1

公开(公告)日：2024-05-23

申请号：US18334531

申请日：2023-06-14

Applicant: Genentech, Inc.

Inventor： Jane Grogan ,  Robert J. Johnston ,  Bryan Irving ,  Jason Hackney ,  Xin Yu ,  Dan Eaton ,  Kristin Bowles ,  Laetitia Comps-Agrar

IPC: C07K16/28 ,  A01K67/0276 ,  A61K39/395 ,  A61K45/06 ,  C07K14/705 ,  C07K16/30

CPC classification number: C07K16/2803 ,  A01K67/0276 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  C07K14/70596 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3038 ,  C07K16/3046 ,  C07K16/3053 ,  C07K16/3061 ,  C07K16/3069 ,  A61K2039/507

Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.

公开(公告)号：US20140065135A1

公开(公告)日：2014-03-06

申请号：US13954796

申请日：2013-07-30

Applicant: Genentech, Inc.

Inventor： Bryan Irving ,  Henry Chiu ,  Heather Maecker ,  Sanjeev Mariathasan ,  Sophie M. Lehar ,  Yan Wu ,  Jeanne Cheung

IPC: C07K16/28 ,  A61K45/06 ,  A61K39/395 ,  A61K39/00

CPC classification number: C07K16/2827 ,  A61K31/7068 ,  A61K39/00 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/1063 ,  C07K16/22 ,  C07K16/28 ,  C07K16/30 ,  C07K16/3046 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/71 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/423 ,  Y02A50/489 ,  Y02A50/492 ,  A61K2300/00

Abstract: The present application relates to methods of using anti-PD-L1 antibodies to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.

Abstract translation: 本申请涉及使用抗PD-L1抗体来增强T细胞功能以上调细胞介导的免疫应答和治疗T细胞功能障碍（包括感染（例如急性和慢性））和肿瘤免疫的方法。

公开(公告)号：US20210332132A1

公开(公告)日：2021-10-28

申请号：US17367133

申请日：2021-07-02

Applicant: Genentech, Inc.

Inventor： Jane Grogan ,  Robert J. Johnston ,  Bryan Irving ,  Jason Hackney ,  Xin Yu ,  Dan Eaton ,  Kristin Bowles ,  Laetitia Comps-Agrar

IPC: C07K16/28 ,  A01K67/027 ,  C07K14/705 ,  A61K39/395 ,  A61K45/06 ,  C07K16/30

Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.

公开(公告)号：US10646567B2

公开(公告)日：2020-05-12

申请号：US15635920

申请日：2017-06-28

Applicant: Genentech, Inc.

Inventor： Heather Maecker ,  Bryan Irving

IPC: C07K16/30 ,  A61K31/4184 ,  A61K31/4355 ,  A61K31/44 ,  A61K31/4523 ,  A61K31/519 ,  A61K39/395 ,  A61K47/62 ,  C07K16/28 ,  A61K47/64 ,  A61K39/00

Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and a MEK inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.

公开(公告)号：US09873740B2

公开(公告)日：2018-01-23

申请号：US14333375

申请日：2014-07-16

Applicant: Genentech, Inc.

Inventor： Jane Grogan ,  Robert J. Johnston ,  Bryan Irving ,  Jason Hackney ,  Xin Yu ,  Dan Eaton ,  Kristin Bowles ,  Laetitia Comps-Agrar

IPC: C07K16/28 ,  A61K39/395 ,  A01K67/027 ,  C07K14/705 ,  A61K45/06 ,  C07K16/30 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/0331 ,  A01K2267/0387 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/507 ,  C07K14/70596 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3038 ,  C07K16/3046 ,  C07K16/3053 ,  C07K16/3061 ,  C07K16/3069 ,  C07K2319/30 ,  Y02A50/466

Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.

公开(公告)号：US20210340253A1

公开(公告)日：2021-11-04

申请号：US17367094

申请日：2021-07-02

Applicant: Genentech, Inc.

Inventor： Jane Grogan ,  Robert J. Johnston ,  Bryan Irving ,  Jason Hackney ,  Xin Yu ,  Dan Eaton ,  Kristin Bowles ,  Laetitia Comps-Agrar

IPC: C07K16/28 ,  A01K67/027 ,  C07K14/705 ,  A61K39/395 ,  A61K45/06 ,  C07K16/30

Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.

公开(公告)号：US09895441B2

公开(公告)日：2018-02-20

申请号：US14556774

申请日：2014-12-01

Applicant: Genentech, Inc.

Inventor： Heather Maecker ,  Bryan Irving

IPC: A61K39/395 ,  A61K31/282 ,  A61K31/519 ,  A61K31/513 ,  C07K16/22 ,  C07K16/28 ,  A61K39/00

CPC classification number: A61K39/3955 ,  A61K31/282 ,  A61K31/513 ,  A61K31/519 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/22 ,  C07K16/2827 ,  A61K2300/00

Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist, chemotherapy and optionally a VEGF antagonist and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.